Privium Fund Management B.V. Sells 18,700 Shares of Ionis Pharmaceuticals, Inc. $IONS

Privium Fund Management B.V. lessened its holdings in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) by 7.0% during the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 248,894 shares of the company’s stock after selling 18,700 shares during the quarter. Ionis Pharmaceuticals accounts for approximately 2.9% of Privium Fund Management B.V.’s investment portfolio, making the stock its 10th biggest position. Privium Fund Management B.V. owned about 0.15% of Ionis Pharmaceuticals worth $16,283,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the stock. Steigerwald Gordon & Koch Inc. acquired a new position in shares of Ionis Pharmaceuticals in the third quarter valued at approximately $25,000. Golden State Wealth Management LLC grew its stake in Ionis Pharmaceuticals by 198.4% during the third quarter. Golden State Wealth Management LLC now owns 376 shares of the company’s stock worth $25,000 after purchasing an additional 250 shares during the period. Mather Group LLC. bought a new stake in shares of Ionis Pharmaceuticals in the 3rd quarter valued at $27,000. Allworth Financial LP increased its stake in Ionis Pharmaceuticals by 231.8% in the second quarter. Allworth Financial LP now owns 740 shares of the company’s stock valued at $29,000 after purchasing an additional 517 shares in the last quarter. Finally, Meeder Asset Management Inc. raised its stake in Ionis Pharmaceuticals by 620.2% during the 3rd quarter. Meeder Asset Management Inc. now owns 713 shares of the company’s stock worth $47,000 after buying an additional 614 shares during the period. Institutional investors own 93.86% of the company’s stock.

Insider Activity

In other news, EVP Shannon L. Devers sold 3,977 shares of the company’s stock in a transaction dated Thursday, January 22nd. The stock was sold at an average price of $81.34, for a total value of $323,489.18. Following the completion of the transaction, the executive vice president owned 22,541 shares of the company’s stock, valued at $1,833,484.94. This represents a 15.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Eugene Schneider sold 9,302 shares of the stock in a transaction dated Friday, January 16th. The shares were sold at an average price of $75.59, for a total transaction of $703,138.18. Following the transaction, the executive vice president directly owned 63,890 shares of the company’s stock, valued at $4,829,445.10. This trade represents a 12.71% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 277,891 shares of company stock worth $21,730,823. 2.60% of the stock is currently owned by insiders.

Ionis Pharmaceuticals Stock Down 1.4%

NASDAQ:IONS opened at $82.67 on Friday. The company has a debt-to-equity ratio of 0.96, a current ratio of 2.79 and a quick ratio of 2.78. The firm’s 50-day moving average price is $80.25 and its 200-day moving average price is $66.21. Ionis Pharmaceuticals, Inc. has a 1-year low of $23.95 and a 1-year high of $86.15. The company has a market capitalization of $13.39 billion, a PE ratio of -48.92 and a beta of 0.28.

Ionis Pharmaceuticals (NASDAQ:IONS) last released its quarterly earnings data on Wednesday, October 29th. The company reported ($0.80) EPS for the quarter, beating the consensus estimate of ($1.15) by $0.35. The company had revenue of $156.72 million for the quarter, compared to analysts’ expectations of $131.75 million. Ionis Pharmaceuticals had a negative return on equity of 44.26% and a negative net margin of 26.45%.Ionis Pharmaceuticals’s revenue was up 17.2% compared to the same quarter last year. During the same period last year, the firm posted ($0.95) earnings per share. On average, equities analysts predict that Ionis Pharmaceuticals, Inc. will post -3.5 EPS for the current fiscal year.

Analyst Ratings Changes

IONS has been the topic of several analyst reports. Barclays initiated coverage on Ionis Pharmaceuticals in a research report on Wednesday. They set an “overweight” rating and a $95.00 target price on the stock. Needham & Company LLC raised their price target on shares of Ionis Pharmaceuticals from $78.00 to $90.00 and gave the stock a “buy” rating in a research note on Thursday, October 30th. Bank of America upped their price objective on shares of Ionis Pharmaceuticals from $86.00 to $97.00 and gave the company a “buy” rating in a report on Tuesday, December 9th. Morgan Stanley lifted their price target on Ionis Pharmaceuticals from $90.00 to $94.00 and gave the company an “overweight” rating in a research report on Thursday, October 30th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Ionis Pharmaceuticals in a research note on Thursday, January 22nd. One research analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $86.45.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc is a biotechnology company focused on the discovery and development of RNA-targeted therapies designed to modulate gene expression. The company’s proprietary antisense oligonucleotide (ASO) technology enables the selective binding of short synthetic strands of nucleic acids to messenger RNA (mRNA), thereby inhibiting or altering the production of disease-causing proteins. Ionis’ pipeline spans a range of therapeutic areas, including neurological disorders, cardiovascular conditions, metabolic diseases and rare genetic disorders.

Since its founding in 1989 by Dr.